Cerus Endovascular is an ISO 13485:2016 certified company. © 2019 Cerus Endovascular Inc. All rights reserved.

Cerus Endovascular Inc. 47757 Fremont Boulevard , Fremont, CA 94538 USA

APM007-01.B 20th January  2020

Tel: +1 (510) 651 4000

Cerus Press Releases 

Cerus Endovascular Expands Intellectual Property Portfolio Brings Patent Portfolio to Five Issued U.S. Patents and over 20+ Pending Patent Applications 

27 November 2018

 

Cerus Endovascular Ltd., a privately held medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiological devices and delivery systems to treat acute, life-threatening intracranial aneurysms, today announced it has been granted U.S. Patent No. 10,130,372. The U.S. patent covers the unique construction of two of the Company’s lead devices, Contour Neurovascular System™ and NEQSTENT™. 

The Company’s patent portfolio includes global filings pursuing a corresponding scope of patent protection. With the issuance of this key patent, the Company has five issued US patents to date and over 20+ pending patent applications worldwide. 

“We are pleased to add to our growing portfolio of intellectual property,” said Cerus Endovascular President Stephen Griffin, PhD. “We have developed a portfolio of novel, high value-added and clinically differentiated aneurysm treatment technologies that have formed a platform to address the insufficiently met clinical needs of today’s $1 billion, and growing, intracranial aneurysm market.” 

“In developing our platform, we have identified some of the shortcomings of existing technologies. Not too long ago, coiling was a major evolution, but technology has progressed. Today, instead of putting 7-10 coils in an aneurysm, we are looking at much faster treatments that equate to better success rates. We recognized the need for advancement in this field, and we believe our technology is going to be the next evolutionary step,” concluded Dr. Griffin. 

Contour Neurovascular System™ and NEQSTENT are revolutionary low-profile implantable devices for deployment across the neck of an aneurysm. The unique shape and features of the devices allow physicians to treat a range of aneurysm morphologies, including wide-neck and bifurcation aneurysms. 

Cerus Endovascular Enrolls First Patients in CERUS Study to Treat Intra-Cranial Aneurysms Using Contour Neurovascular System™ to Reduce the Risk of Rupture 

13 November, 2018

 

Cerus Endovascular Ltd., a privately held medical device company engaged in developing interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysms, today announced enrollment of the first patients in the CERUS Study (Contour Neurovascular System European Pre-Market Unruptured Aneurysm Study). The CERUS study is designed to assess the safety of the company’s Contour Neurovascular System™, which is designed to reduce the risk of rupture when treating patients with intra-cranial aneurysms. Intracranial aneurysms occur at the rate of nine per 100,000 with a wide range; in some countries, up to 20 per 100,0001 

CERUS is a prospective, 30-patient, single-arm, multi-center, pre-market trial. The study is expected to complete enrollment within the next four months and is being conducted at 10 leading European neurological centers in Germany, France, Austria and Denmark. Co-principal investigator, Prof. Dr. Thomas Liebig, of Ludwig Maximillian’s University Hospital, Munich has performed three of the first four cases with the fourth performed at University Hospital Schleswig-Hostein, Kiel. 

When asked about his impression, Prof. Liebig said, “The Contour System combines the benefits of flow disruption and redefinition of the aneurysm-to-parent vessel- border without any material in the parent artery. Thus, it doesn´t mandate long-term antiplatelet therapy. Sizing was straightforward in these first cases and was done with regard to the neck only since the Contour does not aim for bulk replacement of the aneurysmal cavity. Angulation and irregularity of the aneurysm dome seemed to play a lesser role, as well. We are aware of the need for a more valid database with more cases to support these impressions but at the moment we are quite content with our initial experience and look forward to the Co-investigators experiences and to the first control visit of the patients we have treated so far.” 

1 According to Karger Publishers in Basel, Switzerland, a globally active medical and scientific publishing company. 

Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne

 

18 September, 2018  

 

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysm, today announced it has appointed John Kilcoyne to its board of directors, effective immediately. 

Mr. Kilcoyne brings more than 30 years of experience in the medical device market to the Cerus Endovascular Board. Most recently, Mr. Kilcoyne was chief executive officer of ReVision Optics. Prior to ReVision Optics, he served as chief executive officer and chairman of Micrus Endovascular, which he took public and then successfully led for six years until its sale to Johnson & Johnson in 2010. From 2002 to 2004, he served as president and chief executive officer of medical device company Solace Therapeutics. Prior to Solace, he served as the president and chief executive officer of Endonetics, Inc. until its acquisition by Medtronic in 2001. Mr. Kilcoyne received his B.S. from Cornell University. 

“John has a proven track record of advancing companies from development to commercial-stage operations,” said Sam J. Milstein, PhD, lead director of Cerus Endovascular. “In addition to strategy and commercialization skills, John brings to Cerus a deep understanding of the needs of patients as well as doctors in the treatment of vascular disease and neurological conditions, and we look forward to benefitting from his counsel.” 

Mr. Kilcoyne stated, “This is an exciting time to join the Cerus Endovascular Board as the company is keenly focused on developing compelling therapeutic devices for the treatment of hemorrhagic stroke – in particular its novel aneurysm treatments, which address a significant unmet clinical need. I look forward to providing my support as the Cerus team works diligently to improve patient outcomes and drive shareholder value.”

Cerus Endovascular Promotes Stephen Griffin, PhD, to President: 

Company On-Track to Achieve Key Clinical and Regulatory Milestones 

11 May, 2018 

 

Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm, today announced the promotion of Stephen Griffin, PhD, to president of the company, effective immediately. Dr. Griffin had previously served as the company’s chief technology officer since joining in 2014. 

“For the past four years, Stephen has been an integral part of the Cerus team, and it gives the Board great satisfaction to recognize his vast contributions through his promotion to president,” said Sam J. Milstein, PhD, lead director of the company. “In addition to inventing or co-inventing Cerus’s portfolio of interventional neuroradiology devices, including the Contour Neurovascular System™, as well as its intra-saccular coil assist neck bridge technology and microcatheters, Stephen has played a key role in their clinical advancement while also forging relationships with key opinion leaders and pursuing strategic collaborations. The Board looks forward to the continuity of Stephen’s leadership as Cerus works to bring its novel aneurysm treatments to market while creating significant value for its investors.” 

“I am honored to accept the role of president of Cerus Endovascular at this important time in the company’s evolution,” said Dr. Griffin. “We are working toward a number of important milestones this year, including CE Mark and FDA approval for our family of microcatheters, the first of which has been submitted for approval in the U.S.

 

We are also working toward completion of CE Mark trial enrollment of the Contour Neurovascular System™, and the initiation of activities to support an investigational device exception (IDE) study of both the Contour Neurovascular System™ and the intra-saccular neck bridge device technology. We believe these technologies have the potential to significantly advance the field of aneurysm therapy, and we continue to work diligently to bring these treatment options to patients who need them.” 

Prior to joining Cerus Endovascular, Dr. Griffin founded a medical device and technology consultancy, Griffin Biomedical, which counted Cerus Endovascular among its clients. Before that, he served as vice president of research and technology development at Covidien (which was acquired by Medtronic in 2015) and, before that, director of research and development at Nellix Endovascular. Prior to joining Nellix, he served as director of research and development at Cordis (a unit of J&J, which was sold to Cardinal Health in 2015).

 

Earlier in his career, Dr. Griffin served in various research and development roles of increasing responsibility at Boston Scientific. He received his PhD and his BS in Materials Science from the University of Limerick. 

The company also announced that Todd Derbin is no longer chief executive officer or chairman of the company or its U.S. subsidiary. 

Cerus Endovascular Provides Corporate Update:

Controlled commercial roll-out of the Contour Neurovascular System™ progressing, with 25 key sites confirmed Highly successful first-in-man implantation of the NEQSTENT™ Intra-Saccular Stent completed, with additional cases anticipated

7 September, 2017

 

Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm, today provided an update on its lead development programs, including the Contour Neurovascular System™ as well as the NEQSTENT™ Intra-Saccular Stent.

“The past few months have been transformational for our company, as we have moved aggressively to further advance our portfolio of clinically differentiated aneurysm treatments and begin the transition to a commercial-stage company with the roll-out of Contour Neurovascular System™in CE Marking countries.” 

 

“As we enter this new phase, we look forward to building upon the successful outcomes seen to date, and to planned discussions with the U.S. Food & Drug Administration (FDA) and other regulatory agencies. We strongly believe that our innovative devices have the potential to revolutionize aneurysm treatment, and we are eager to make this technology more broadly available to patients in need.”   

Contour Neurovascular System™

Since announcing CE Mark approval of the Contour Neurovascular System™ in June 2017, Cerus Endovascular has made steady and continued progress toward transforming into a commercial-stage company. To date, 25 sites in Europe have been confirmed for limited commercial release of the system on a direct sales basis. Additionally, the company has assembled a steering committee comprised of leading experts in the field of aneurysm treatment to assist in the screening of appropriate patient cases. 

NEQSTENT™ Intra-Saccular Stent

Cerus Endovascular also announced today a highly-successful first-in-man implantation of the NEQSTENT™ Intra-Saccular Stent at Odense University Hospital in Denmark. Additional cases are planned. The company is in the process of finalizing its regulatory submission to European authorities and is targeting CE Mark approval in the second quarter 2018.   

Cerus Endovascular has successfully completed all required chronic toxicity, genotoxicity and carcinogenicity testing for both Contour and NEQSTENT™ in preparation for a pre-IDE meeting with FDA in the coming months.